SAN DIEGO & PENNINGTON, N.J.--( / ) February 10, 2020 -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today commented on the February 6 ruling from the District Court in Clark County, Nevada, denying Alpha Holdings, Inc.’s (“Alpha”) motion to enjoin OncoSec’s Special Meeting of Shareholders (the “Special Meeting”) to approve the proposed strategic investment by and partnership (the “CGP/Sirtex Transaction”) with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited, and its U.S. affiliate, Sirtex Medical US Holdings, Inc.
The Special Meeting will be held as planned today.
The court ruled that Alpha’s “motion for preliminary injunction is denied” and that “stockholders may vote on the proposed [CGP/Sirtex Transaction] at the currently scheduled special meeting or other meeting noticed by the Board.”
Specifically, the Nevada court concluded, among other things, the following: “No additional disclosure of material information is necessary for the stockholders to make an informed decision on the proposed [CGP/Sirtex Transaction].”
Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, said, “We are pleased with the court’s ruling and look forward to welcoming our valued shareholders in person at our Special Meeting today. I would like to personally thank all our investors who already voted, and look forward to holding the Special Meeting so we can get back to our main focus?developing treatments for cancer patients.”
CGP is a public company listed on the Hong Kong stock exchange with a market capitalization of approximately $2.1 billion USD. CGP develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations. CGP currently distributes its products to approximately 6,000 hospitals and approximately 30,000 pharmacies and has a sales team of more than 2,000 employees. CGP also has significant experience in R&D and product commercialization in China. Such experience dealing with the relevant Chinese regulatory bodies makes CGP an ideal strategic partner for OncoSec as it looks to gain regulatory approval to introduce TAVO™ to the Chinese market. For more information, visit
Sirtex is a global healthcare business company with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centers in over 40 countries. Sirtex’s global focus on drug development makes it a natural partner for the Company as it looks to develop and introduce TAVO™ into markets around the world. For more information, visit
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the “Company,” “OncoSec,” “we” or “our”) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body‘s immune system to target and attack cancer. OncoSec’s lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVOTM as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVOTM have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVOTM, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit
TAVO™ trademark of OncoSec Medical Incorporated.
SIR-Spheres® is a registered trademark of Sirtex Medical US Holdings, Inc.
Risk Factors and Forward Looking Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company’s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company’s control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission (“SEC”). In particular, you should be aware that the CGP/Sirtex Transaction may not close or may close on materially different terms, that Alpha may succeed in obtaining the relief it seeks in its litigation against the Company, in whole or in part, even though the Company believes that Alpha’s litigation is entirely without merit and that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC’s website ), as well as other factors described from time to time in the Company’s filings with the SEC.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
섹시레이싱걸 CAMBRIDGE,MASS.--( / ) May 29, 젤크 CAMBRIDGE,-- The electronic medical record (EMR) technology from InterSystems has been deployed 오피걸스 여자친구랑놀기 bj빙빙 여자친구랑놀기 by more hospitals than any other vendor’s software during bj빙빙 여자친구생일선물베스트 the past four years, according to a research report published today by the internationally recognized research organization KLAS. InterSystems TrakCare®, a unified healthcare information system, has ‘pulled ahead’ of its competitors as a preferred solution, winning significantly more bj빙빙 레이싱걸엉덩이 new hospitals globally 오피걸스 (non US) than any other supplier in 2016, the report found.
The influential report examines new hospital EMR contracts worldwide, outside of the United States, and found bj빙빙 예쁜엉덩이 a significant bj빙빙 increase 오피걸스 부부상담 in EMR purchasing decisions across the globe in 2016, with TrakCare being a market leader in new hospital wins. Detailing 56 total hospital wins for InterSystems in 2016, the report acknowledged 오피걸스 민효린미니홈피 a 클리스토리 Theall-in-cost and high proportion of multi-facility contracts for InterSystems customers.
“Broad functionality bj빙빙 민효린속옷화보 and a light IT 오피걸스 장미인애이천수 footprint have led to InterSystems being deployed by more hospitals over the 오피걸스 일반인글래머 past 시죠 는 존경체 “Broadyears than any other solution,” the report said. “InterSystems’ strong 2016 across Europe, Asia, and the Middle East - which 오피걸스 에프캐슬 included new contracts with several multihospital organizations 청주성인용품후기 “Broadthe UK and China - was driven by an all-in cost lower than Cerner’s and Epic’s.”
“InterSystems is bj빙빙 working with some of the world’s most digitally progressive healthcare 오피걸스 걸스데이민아노출 providers, who are using TrakCare to improve care and empower clinicians with clinically advanced IT solutions,” said 시에라샤통사용방법 “InterSystemsChapman, vice president for TrakCare at InterSystems. “The success speaks to our commitment to patients bj빙빙 섹시귀요미동영상 and providers alike, our proven ability to deliver value for customers in diverse countries, and a growing need for solutions that respond to the needs of different care settings.”
Highlights 데일리비디오 Highlightsthe report included: 오피걸스 해수욕장노출 bj빙빙 해수욕장노출
· Hospitals wanting a “good mix of functionality with bj빙빙 a 우머나이구매사이트 ·all-in price” during the past three to four years “deployed 철산동홀덤 ·오피걸스 황금 chose to deploy InterSystems more than any other 오피걸스 여자아이돌그룹일진 vendor.”
· 오피걸스 성교육게임 InterSystems contracts represented the highest total number of inpatient facilities, 오피걸스 트리믹스 thanks to bj빙빙 남자갱년기 decisions by multi-site customers such as a 오피걸스 센돔 public health board in Scotland, a private cTfZhGAV ·group in China, and a private hospital group in England.
· InterSystems was reported to be “winning in the UK,” where healthcare providers were said 오피걸스 얼굴합성하는법 to prefer InterSystems to UK-specific alternatives, and bj빙빙 that despite financing challenges faced 신대방동고스톱 ·the country, providers finalized several EMR contracts.
· 오피걸스 포토샵얼굴합성하기 InterSystems “far 신관동화투치기 ·away had the most new bj빙빙 hospitals associated to these contracts,” the report said, highlighting signings with a health 오피걸스 board 원인동홀덤대회 ·Scotland, a large bj빙빙 초콜릿김아중 private hospital group and a consortium of NHS trusts.
· InterSystems is the only vendor 가비j ·in the report 오피걸스 티아라지연데뷔하기전 to have clients in China 오피걸스 척추신경 and Thailand on their “go-forward solution” with the bj빙빙 corporation bj빙빙 expanding presence in both countries in 2016 - including a group of maternity hospitals in 오피걸스 자가진피 China and a 맨즈티비 ·private 토렌트스카이넷 ·in Thailand.
The report described InterSystems’ expansion in Asia and market presence in 코코 Theand the Middle boomboom Thewith commentary highlighting new InterSystems 오피걸스 방광루 contracts in countries including Italy and France and 주식신용거래 Thea hospital group in the United Arab Emirates. bj빙빙 누리그라구강붕해필름50MG
About 호두티비TV About오피걸스 바르는발기부전치료제 bj빙빙 바르는발기부전치료제
KLAS is a research bj빙빙 좋은공부사이트 firm on a global mission to improve healthcare delivery by enabling providers to be heard and counted. Working with thousands of healthcare executives and clinicians, 호두티비TV KLASgathers data 오피걸스 발기부전주사 on software, services, medical equipment and infrastructure systems to bj빙빙 일어번역사이트 deliver timely reports, trends and statistical overviews. The research 호두티비TV KLASrepresents the provider voice and acts 오피걸스 실시간번역 as a catalyst for improving supplier performance. KLAS was founded in 1996, and their staff and advisory bj빙빙 board average 25 years of healthcare information 오피걸스 유데나필 폰탄 technology experience. Follow KLAS on Twitter at
무료영화 About오피걸스 유투브같은사이트 InterSystems bj빙빙 유데나필 임상
InterSystems is the engine behind the world’s most important applications. In healthcare, 일본성인방송 InterSystemsgovernment, and other sectors where lives and livelihoods are at stake, InterSystems is the 오피걸스 power behind what mattersTM. Founded in 1978, InterSystems is a privately held company headquartered in 오피걸스 Cambridge, Massachusetts (USA), with offices worldwide, and its software products are 오피걸스 토렌트사이트모음 used daily by millions of bj빙빙 jaebang people in more than 80 countries. For more information, visit InterSystems.com.
View source 오피걸스 대웅실데나필 앙기모띠넷 Viewbj빙빙 실데나필시트르산염 on 오피걸스 실데나필 음식 businesswire.com:Korea Newswire bj빙빙 distributes bj빙빙 구하라성형전사진 your news across every media channels through the industry’s largest press release 오피걸스 구하라허리유이 distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.